// App-Quantinova.ai

1250 : Antitumor activities of CD161, a structurally novel and orally bioavailable BET inhibitor, in leukemia and triple negative breast cancer cells in vitro and in vivo

Researchers

Presenter

  • Longchuan Bai

Principal Investigators

  • Yujun Zhao

  • Liu Liu

  • Chao-Yie Yang

  • Donna McEachern

  • Jeanne Stuckey

  • Jennifer Meagher

  • Bo Wen

  • Duxin Sun

  • Shaomeng Wang

Medical Centers

  • University of Michigan, Ann Arbor, MI

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

  • Hematological malignancies

  • Breast cancer

  • Solid malignancies

Biomarkers

  • CREB-binding protein

  • Defensin Beta 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved